Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility where there are wide-spread medical needs.

Further reading »


Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »


The Share

Latest News

Oasmia gives notice of Extraordinary General Meeting

May 7 2015
The company is now entering into a new phase of its development. In consideration of this and other things certain organizational changes will be made. Against this background, the EGM will primarily be presented to, and make a resolution of, a change of the board of directors.
Further reading »

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)

May 7 2015
The shareholders in Oasmia Pharmaceutical AB (publ) reg. no. 556332-6676 (the “Company”) are hereby convened to the extraordinary general meeting on Thursday 28 May 2015, at 14.00 at floor 7, Vallongatan 1, Uppsala. The registration commences at 13.30.
Further reading »

Results from Oasmia’s Phase III study will be presented at ASCO

April 24 2015
Uppsala, Sweden – April 24, 2015. The pharmaceutical company Oasmia Pharmaceutical announced today that data from the recently completed Phase III study with Paclical® for treatment of ovarian cancer will be presented at the 2015 ASCO Annual Meeting in Chicago. The principal investigator of the study, Ignace Vergote, will perform the presentation.
Further reading »

bottom